Alzheimer’s Therapy Urged to Embrace a Multi-Pathway Approach

A new Science China Life Sciences review argues that Alzheimer’s arises from a complex network of factors—amyloid and Tau pathology, genetics, aging, and systemic health—making single-target drugs insufficient. The authors urge a holistic strategy that tackles multiple disease pathways, including Tau and aging-related changes, genetic risk, and gut-brain interactions, while leveraging tools like iPSC-derived organoids, CRISPR, and early biomarkers (e.g., plasma pTau217) to guide precision therapies and possibly delay or prevent progression.